July 26th 2024
SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Closing Thoughts on Data Updates From IASLC 2023 World Conference on Lung Cancer
September 21st 2023Following their review of data from the IASLC 2023 World Conference on Lung Cancer with expert Stephen Liu, MD, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, highlight key takeaways and future directions in care.
Watch
Data From FLAURA2: Osimertinib With or Without Chemotherapy in Metastatic NSCLC
September 21st 2023Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer.
Watch
Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC
September 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.
Read More
Nivolumab/Ipilimumab Continues to Show OS Benefit in NSCLC at 6 Years
September 18th 2023With a minimum of 73.5 months of follow-up, nivolumab plus ipilimumab showed a benefit in overall survival in patients with treatment-naive stage IV or recurrent non–small cell lung cancer with no known EGFR/ALK alterations.
Read More
Significant Benefit Shown with Perioperative Durvalumab/Chemo in Resectable NSCLC
September 16th 2023According to research led by Tetsuya Mitsudomi, MD, perioperative durvalumab plus chemotherapy may be better than placebo plus chemotherapy for the treatment of resectable non–small cell lung cancer.
Read More
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
September 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.
Read More
CHRYSALIS Study Shows Potential of Amivantamab/Lazertinib in EGFRm NSCLC
September 5th 2023Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Watch
Phase 2 of ARROS-1 Trial Assessing NVL-520 in Solid Tumors Commences
September 5th 2023As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.
Read More
ALINA Study of Alectinib Meets Primary DFS End Point in ALK+ NSCLC
September 1st 2023Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.
Read More
The Growing Role of Immunotherapy in Targeting NSCLC
August 30th 2023During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.
Read More
Patient Characteristics Influence Choice of Chemo/IO Regimen in NSCLC
August 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.
Read More
Amivantamab Plus Lazertinib May Be a Future Treatment Option for NSCLC
August 17th 2023In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.
Read More
Use of ICI Therapy Beyond 2 Years Yields No Outcome Benefit in NSCLC
August 10th 2023Findings from a study published in JAMA Oncology showed no survival difference in fixed duration immune checkpoint inhibitor group vs the indefinite-duration group among patients with non–small cell lung cancer
Read More
Efficacy and Safety of Tusa with Pembrolizumab and Chemotherapy in NSCLC: CARMEN-LC05 Study
August 8th 2023Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.
Watch